Community

XLS

Spending on community involvement

 

 

 

 

 

 

 

 

 

€ million

 

2014

 

2015

 

20161,2

 

2017

1

Includes Sigma-Aldrich as of 2016

2

From 2016 on, we are separating spending on patient support programs such as our Erbitux® China Patients Assistance Program from our community involvement figures.

Total spending

 

50.8

 

100.0

 

43.0

 

33.8

We calculate the value of pharmaceutical product donations according to the WHO Guidelines for Medicine Donations; for other product donations, we apply their fair value.

XLS

Community involvement spending by region1

 

 

 

 

 

 

 

 

 

 

 

 

 

Europe

 

North America

 

Asia-Pacific (APAC)

 

Latin America

 

Middle East and Africa (MEA)

 

 

 

 

 

 

 

 

 

 

 

2016

 

 

 

 

 

 

 

 

 

 

1

This table presents the regions across the globe in which we support initiatives. For projects that benefit multiple regions, we have calculated the amount per region by dividing the project spending evenly per country.

€ million

 

10.1

 

2.3

 

4.4

 

1.1

 

25.1

%

 

24

 

5

 

10

 

3

 

58

 

 

 

 

 

 

 

 

 

 

 

2017

 

 

 

 

 

 

 

 

 

 

€ million

 

8.7

 

2.9

 

3.2

 

0.5

 

18.5

%

 

26

 

9

 

9

 

1

 

55

XLS

Focus of our local community involvement1

 

 

 

 

 

 

 

 

 

%

 

2014

 

2015

 

20162,3,4

 

2017

1

Based on number of projects

2

Includes Sigma-Aldrich as of 2016

3

Since 2016, we have integrated our global projects into our community outreach figures, specifically the Global Pharma Health Fund, the Praziquantel Donation Program and the Deutsche Philharmonie sponsored by Merck KGaA, Darmstadt, Germany. This change in approach was due to the increasingly international nature of our efforts. We are spearheading a rising number of global projects that account for a growing percentage of our project portfolio. To ensure maximal accuracy, we are therefore including all international initiatives in our figures as of 2016.

4

From 2016 on, we are separating spending on patient support programs such as our Erbitux® China Patients Assistance Program from our charitable spending figures.

Health

 

33

 

33

 

35

 

38

Education and culture

 

38

 

33

 

36

 

43

Environment

 

10

 

7

 

5

 

4

Disaster relief

 

4

 

6

 

2

 

2

Other

 

15

 

21

 

22

 

13

XLS

Motivations for our community involvement1

 

 

 

 

 

 

 

 

 

%

 

2014

 

2015

 

20162,3,4

 

2017

1

Based on total spending on all projects

2

Including Sigma-Aldrich as of 2016

3

Since 2016, we have been integrating our global projects into our community outreach figures, specifically the Global Pharma Health Fund, the Praziquantel Donation Program and the Deutsche Philharmonie sponsored by Merck KGaA, Darmstadt, Germany. This change in approach was due to the increasingly international nature of our efforts. We are spearheading a rising number of global projects that account for a growing percentage of our project portfolio. To ensure maximal accuracy, we are therefore including all international initiatives in our figures as of 2016.

4

As of 2016, we are separating patient support programs such as our Erbitux® China Patients Assistance Program from our charitable spending.

Charitable activities

 

9

 

3

 

4

 

9

Community investment

 

59

 

92

 

87

 

84

Commercial initiatives in the community

 

32

 

5

 

9

 

7

We categorize the motivations for our activities based on the London Benchmarking Group model as well as the guidelines of the Bertelsmann Foundation for corporate social responsibility. Projects that primarily aim to make improvements within the community are classified as community investment.

Initiatives that are predominantly aimed at company-relevant factors such as image or personnel recruitment are classified as commercial initiatives in the community. Charitable activities cover any other projects that benefit a charitable organization, but cannot be listed under either of the other two motivation categories due to missing data or their narrow scope.

GRI disclosures

Cookie Disclaimer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re OK with this. You can change which cookies are set at any time - and find out more about them in our cookie policy. Privacy Statement